Health · 1 sources covering this

STAT+: House votes to temporarily block Trump plan to politicize federal grants

The House voted to pass a stopgap funding bill that, for now, blocks a White House proposal to give political appointees more control over research grants.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: House votes to temporarily block Trump plan to politicize federal grants
The House voted to pass a stopgap funding bill that, for now, blocks a White House proposal to give political appointees more control over research grants.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/30f49f22a9e242f966cae13a409af04ab061320f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: House votes to temporarily block Trump plan to politicize federal grants"></iframe>

STAT+: House votes to temporarily block Trump plan to politicize federal grants

How 1 sources are covering this

STAT+: House votes to temporarily block Trump plan to politicize federal grants

More from Health

Opinion: I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field

STAT+: 5 burning questions on Trump’s latest deals with drugmakers

STAT+: Novartis gets multiple sclerosis win with BTK inhibitor

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: House votes to temporarily block Trump plan to politicize federal grants

More from Health

Opinion: I’m a reproductive psychiatrist. The Lindsay Clancy trial will cause terrible damage to my field

STAT+: 5 burning questions on Trump’s latest deals with drugmakers

STAT+: Novartis gets multiple sclerosis win with BTK inhibitor

STAT+: Pharmalittle: We&#8217;re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more